Government agencies that approve drugs are actually 96% funded by Big Pharma. Result: Harmful Vaccines, Safe Treatments Banned, Borders Closed, Small Businesses Destroyed
Posted by freedomforall 11 months, 1 week ago to Politics
Excerpt:
"Over the past decades, regulatory agencies have seen large proportions of their budgets funded by the industry they are sworn to regulate, explains investigative journalist Maryanne Demasi.
Industry fees to the US Food and Drug Administration (FDA) have increased 30 fold – from around $29m in 1993 to $884m in 2016, while in Europe, industry fees now fund 89% of the European Medicines Agency (EMA), up from 20% in 1995.
In 2005, the UK House of Commons’ health committee evaluated the influence of the drug industry on health policy. But nearly two decades on, little has changed, and industry funding of drug regulators has become the international norm.
The BMJ asked six leading regulators, in Australia, Canada, Europe, Japan, the UK, and US, a series of questions about their funding, transparency in their decision making (and of data), and the rate at which new drugs are approved.
Of these, Australia had the highest proportion of budget from industry fees (96%) and in 2020-2021 approved more than nine of every 10 drug company applications."
"Over the past decades, regulatory agencies have seen large proportions of their budgets funded by the industry they are sworn to regulate, explains investigative journalist Maryanne Demasi.
Industry fees to the US Food and Drug Administration (FDA) have increased 30 fold – from around $29m in 1993 to $884m in 2016, while in Europe, industry fees now fund 89% of the European Medicines Agency (EMA), up from 20% in 1995.
In 2005, the UK House of Commons’ health committee evaluated the influence of the drug industry on health policy. But nearly two decades on, little has changed, and industry funding of drug regulators has become the international norm.
The BMJ asked six leading regulators, in Australia, Canada, Europe, Japan, the UK, and US, a series of questions about their funding, transparency in their decision making (and of data), and the rate at which new drugs are approved.
Of these, Australia had the highest proportion of budget from industry fees (96%) and in 2020-2021 approved more than nine of every 10 drug company applications."
